Antares Pharma, Inc. (NASDAQ: ATRS) announced its fourth-quarter financial results on Tuesday.
According to the drugmaker, revenue for the fourth quarter was $14 million, which missed analysts’ estimates of $15 million. In addition, the company reported a loss of $3.7 billion, or $0.02 per share, for the fourth quarter, compared with net loss of $4.5 million for the same period last year. The result was better than the estimates of $0.03 per share net loss.
For the full year 2017, the company announced revenue of $54.5 million, and reported loss of $16.7 million, or $0.11 per share, compared with a loss of $24.3 million for 2016.
“I am pleased to report another year of revenue growth driven by an increasing portfolio of proprietary and partnered products. We believe the recent approval of the Makena subcutaneous auto injector product, which utilizes our QuickShot device, could potentially drive further revenue growth in the coming year,” Robert F. Apple, the President and Chief Executive Officer of Antares Pharma, said in the statement on Tuesday.
“We remain focused on growing both our commercial business and our pipeline in 2018 with the potential filing of an investigational new drug application in the second half of this year,” Mr. Apple said.